Table II.
Mean (SE) and Variability (Between Patient) of Parameters Describing the Course of Progression of Parkinson’s Disease in Patients Treated with Placebo Using NLMIXED in SAS®
| Study | Parameter | Mean (SE) | Variability (%) |
|---|---|---|---|
| 1 | Rate of progression (slope) | 0.27 (0.07) | 64.15 |
| Symptomatic effect | 1.24 (3.28) | 44.90 | |
| Rate constant for time to attain maximum symptomatic effect | 0.06 (0.03) | 1,269.30 | |
| LN (baseline UPDRS) | 3.25 (0.04) | 38.85 | |
| 2 | Rate of progression (slope) | 0.13 (0.01) | 64.36 |
| Symptomatic effect | 1.47 (0.59) | 53.13 | |
| LN (rate constant for time to attain maximum symptomatic effect) | 0.35 (1.95) | 62.44 | |
| LN (baseline UPDRS) | 3.12 (0.04) | 34.64 | |
| 3 | Rate of progression (slope) | 0.11 (0.01) | 157.46 |
| Symptomatic effect | 1.59 (0.25) | 117.66 | |
| Rate constant for time to attain maximum symptomatic effect | 2 (fixed) | NE | |
| LN (baseline UPDRS) | 3.19 (0.02) | 41.23 | |
| 4 | Rate of progression (slope) | 0.14 (0.02) | 71.43 |
| Symptomatic effect | NE | NE | |
| Rate constant for time to attain maximum symptomatic effect | 0.08 (0.05) | NE | |
| LN (baseline UPDRS) | 3.11 (0.05) | 42.43 |
Units for rate of progression (slope)—per week; symptomatic effect—UPDRS; rate constant for time to attain maximum symptomatic effect (ke0)—per week
NE could not be estimated, LN natural logarithm, UPDRS Unified Parkinson’s Disease Rating Scale, SE standard error